90-90-90 Target for driving down HIV/AIDS infections worldwide inspires new approach to diabetes

“Diabetes Canada adapting made-in-BC Treatment as Prevention® (TasP®) strategy to diabetes, making 6 million Canadians aware of their status.

Diabetes Canada is adopting the BC Centre for Excellence in HIV/AIDS Treatment as Prevention® (TasP®) approach to tackle the epidemic of diabetes and prediabetes currently affecting over 11 million Canadians. This is the first time the made-in-BC TasP® strategy, and the related global 90-90-90 Target for the control of HIV/AIDS, will be applied to a non-infectious disease.

Read the full story

Leave a Reply

Scroll to Top

The BC-CfE Laboratory is streamlining reporting processes for certain tests in order to simplify distribution and record-keeping, and to ensure completeness of results. Beginning September 2, 2025, results for the ‘Resistance Analysis of HIV-1 Protease and Reverse Transcriptase’ (Protease-RT) and ‘HIV-1 Integrase Resistance Genotype’ tests will be combined into a single ‘HIV-1 Resistance Genotype Report’.
For more details and example reports, please click on the button below